ReviewClinical and experimental hepatology2026
Managing HBV/HIV coinfection: from diagnostics to long-acting antiretroviral therapy.
Review in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection accelerates liver disease progression and increases the risk of hepatocellular carcinoma (HCC). Lifelong HBV-active antiretroviral therapy is the cornerstone of management, while occult HBV infection and isolated anti-HBc serology require careful monitoring, particularly when switching to long-acting regimens lacking HBV activity. Comprehensive diagnostics, including HBV DNA testing, fibrosis assessment, and evaluation of serological profiles, are essential for optimal care. Vaccination with next-generation HBV vaccines (ex. CpG adjuvant, multiantigenic), provides superior immunogenicity and should be prioritized in people living with HIV, especially in prior nonresponders. Regular HCC screening is recommended in individuals with advanced liver disease to enable early detection and intervention. This review summarizes current evidence on diagnostics, therapy, vaccination, monitoring, and cancer prevention, providing practical recommendations to improve outcomes in HIV/HBV coinfected populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.